[Adamantiadi-Behçet syndrome: treatment with recombinant leukocytic interferon]

Ter Arkh. 2001;73(5):43-5.
[Article in Russian]

Abstract

Aim: To evaluate efficacy of synthetic leukocytic interferon (SLI) in patients with severe Adamantiadi-Behçet syndrome (ABS).

Materials and methods: The trial enrolled 18 patients (11 men and 7 women aged 25 to 43 years) with severe ABS. The duration of the disease ranged from 1 to 12 years. Subcutaneous ABS injections in a dose 5 x 10(6) U/m2 for 8 weeks followed by 3 x 10(6) for 16 weeks. The results were estimated by standard clinical and biochemical indices.

Results: All 18 patients responded to the treatment. After the course of treatment 13 patients were in remission for 4-52 months. The rest of the patients were given one more course of treatment.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Behcet Syndrome / diagnosis
  • Behcet Syndrome / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Interferon Type I / administration & dosage
  • Interferon Type I / therapeutic use*
  • Male
  • Recombinant Proteins
  • Time Factors

Substances

  • Antiviral Agents
  • Interferon Type I
  • Recombinant Proteins